{"version":"company-facts.v1","source":"https://secwatch.observer","generated_at":"2026-07-17T07:19:12.133945+00:00","company":{"ticker":"KLRA","cik":2096997,"company_name":"Kailera Therapeutics, Inc."},"pagination":{"limit":100,"returned":3,"next_cursor":null},"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer","counterparties":{},"facts":[{"fact_type":"earnings_release","fact_key":"5a08cb8ec9e0f526ccfa12dc4057416f90084a90","cik":2096997,"ticker":"KLRA","company_name":"Kailera Therapeutics, Inc.","filed_at":"2026-05-26T20:18:46+00:00","payload":{"eps_text":null,"guidance_signal":"none","item_codes_triggered":["2.02"],"net_income_text":null,"period_text":"the first quarter ended March 31, 2026","report_date":"2026-05-26","result_type":"reported_results","revenue_text":null},"claim":"Kailera Therapeutics, Inc. reported financial results for the first quarter ended March 31, 2026.","evidence_excerpt":"On May 26, 2026, Kailera Therapeutics, Inc. (the \"Company\") issued a press release reporting its financial results for the quarter ended March 31, 2026.","confidence":0.85,"filing_url":"https://secwatch.observer/filing/0001193125-26-239362","anchor_url":"https://secwatch.observer/filing/0001193125-26-239362#claim-5a08cb8ec9e0f526ccfa12dc4057416f90084a90","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/2096997/000119312526239362/0001193125-26-239362-index.htm"},{"fact_type":"governance_change","fact_key":"576b1f2b897b05910763691e7575a49fd2a16275","cik":2096997,"ticker":"KLRA","company_name":"Kailera Therapeutics, Inc.","filed_at":"2026-04-20T23:59:59+00:00","payload":{"change_type":"bylaw_amendment","effective_date":"2026-04-20","item_codes_triggered":["5.03"],"summary_text":"Amended and restated bylaws to establish procedures for stockholder proposals and director nominations and conform to charter amendments."},"claim":"Kailera Therapeutics, Inc.: Amended and restated bylaws to establish procedures for stockholder proposals and director nominations and conform to charter amendments (effective 2026-04-20).","evidence_excerpt":"On April 20, 2026, in connection with the closing of the IPO, the amended and restated bylaws of the Company (the “Amended and Restated Bylaws”), previously approved by the Company’s board of directors, became effective.","confidence":0.9,"filing_url":"https://secwatch.observer/filing/0001193125-26-164040","anchor_url":"https://secwatch.observer/filing/0001193125-26-164040#claim-576b1f2b897b05910763691e7575a49fd2a16275","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/2096997/000119312526164040/0001193125-26-164040-index.htm"},{"fact_type":"governance_change","fact_key":"4155bd13189cc843ab47d9dad5700997e7fa77f8","cik":2096997,"ticker":"KLRA","company_name":"Kailera Therapeutics, Inc.","filed_at":"2026-04-20T23:59:59+00:00","payload":{"change_type":"charter_amendment","effective_date":"2026-04-20","item_codes_triggered":["5.03"],"summary_text":"Amended and restated certificate of incorporation to fix authorized common stock, authorize undesignated preferred stock, establish classified board with staggered terms, require cause for director removal, require advance notice, eliminate written consent, and designate exclusive forums."},"claim":"Kailera Therapeutics, Inc.: Amended and restated certificate of incorporation to fix authorized common stock, authorize undesignated preferred stock, establish classified board with staggered terms, require cause for director removal, require advance notice, eliminate written consent, and designate exclusive forums (effective 2026-04-20).","evidence_excerpt":"On April 20, 2026, Kailera Therapeutics, Inc. (the “Company”) filed an amended and restated certificate of incorporation (the “Restated Certificate”) with the Secretary of State of the State of Delaware in connection with the closing of the initial public offering (the “IPO”) of shares of its common stock.","confidence":0.9,"filing_url":"https://secwatch.observer/filing/0001193125-26-164040","anchor_url":"https://secwatch.observer/filing/0001193125-26-164040#claim-4155bd13189cc843ab47d9dad5700997e7fa77f8","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/2096997/000119312526164040/0001193125-26-164040-index.htm"}]}